Your browser doesn't support javascript.
loading
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Müller, Moritz; Posch, Florian; Kiem, Dominik; Barth, Dominik; Horvath, Lena; Stotz, Michael; Schaberl-Moser, Renate; Pichler, Martin; Greil, Richard; Jost, Philipp J; Seeber, Andreas; Amann, Arno; Schlick, Konstantin; Gerger, Armin; Riedl, Jakob M.
Afiliación
  • Müller M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Posch F; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Kiem D; IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria.
  • Barth D; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Horvath L; Department of Internal Medicine V: Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
  • Stotz M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Schaberl-Moser R; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Pichler M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Greil R; IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria.
  • Jost PJ; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Seeber A; Department of Internal Medicine V: Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
  • Amann A; Department of Internal Medicine V: Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
  • Schlick K; IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria.
  • Gerger A; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Riedl JM; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, Graz 8036, Austria.
Ther Adv Med Oncol ; 13: 17588359211039930, 2021.
Article en En | MEDLINE | ID: mdl-34616490
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Med Oncol Año: 2021 Tipo del documento: Article País de afiliación: Austria
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Med Oncol Año: 2021 Tipo del documento: Article País de afiliación: Austria